Journal of Shanghai Jiao Tong University (Medical Science) ›› 2024, Vol. 44 ›› Issue (6): 788-794.doi: 10.3969/j.issn.1674-8115.2024.06.015
• Review • Previous Articles Next Articles
ZHANG Yong1(), LI Weihong1, CHENG Zhipeng1, WANG bin1, WANG Siheng1, WANG Yubin1,2(
)
Received:
2024-01-09
Accepted:
2024-04-12
Online:
2024-06-28
Published:
2024-06-28
Contact:
WANG Yubin
E-mail:840595873@qq.com;wangyb1980@163.com
Supported by:
CLC Number:
ZHANG Yong, LI Weihong, CHENG Zhipeng, WANG bin, WANG Siheng, WANG Yubin. Research status of receptor-interacting protein kinase 1 in regulating cancer progression and immune response[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(6): 788-794.
Add to citation manager EndNote|Ris|BibTeX
URL: https://xuebao.shsmu.edu.cn/EN/10.3969/j.issn.1674-8115.2024.06.015
1 | DEGTEREV A, HUANG Z H, BOYCE M, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury[J]. Nat Chem Biol, 2005, 1(2): 112-119. |
2 | SHAN B, PAN H L, NAJAFOV A, et al. Necroptosis in development and diseases[J]. Genes Dev, 2018, 32(5/6): 327-340. |
3 | DOVEY C M, DIEP J, CLARKE B P, et al. MLKL requires the inositol phosphate code to execute necroptosis[J]. Mol Cell, 2018, 70(5): 936-948.e7. |
4 | SEIFERT L, WERBA G, TIWARI S, et al. The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression[J]. Nature, 2016, 532(7598): 245-249. |
5 | KONDYLIS V, PASPARAKIS M. RIP kinases in liver cell death, inflammation and cancer[J]. Trends Mol Med, 2019, 25(1): 47-63. |
6 | YAN J, WAN P X, CHOKSI S, et al. Necroptosis and tumor progression[J]. Trends Cancer, 2022, 8(1): 21-27. |
7 | MIFFLIN L, OFENGEIM D, YUAN J Y. Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target[J]. Nat Rev Drug Discov, 2020, 19(8): 553-571. |
8 | LI W J, YUAN J Y. Targeting RIPK1 kinase for modulating inflammation in human diseases[J]. Front Immunol, 2023, 14: 1159743. |
9 | HE S D, WANG X D. RIP kinases as modulators of inflammation and immunity[J]. Nat Immunol, 2018, 19(9): 912-922. |
10 | RIEBELING T, KUNZENDORF U, KRAUTWALD S. The role of RHIM in necroptosis[J]. Biochem Soc Trans, 2022, 50(4): 1197-1205. |
11 | WU G W, LI D K, LIANG W, et al. PP6 negatively modulates LUBAC-mediated M1-ubiquitination of RIPK1 and c-FLIPL to promote TNFα-mediated cell death[J]. Cell Death Dis, 2022, 13(9): 773. |
12 | DRABER P, KUPKA S, REICHERT M, et al. LUBAC-recruited CYLD and A20 regulate gene activation and cell death by exerting opposing effects on linear ubiquitin in signaling complexes[J]. Cell Rep, 2015, 13(10): 2258-2272. |
13 | YUAN J Y, AMIN P, OFENGEIM D. Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases[J]. Nat Rev Neurosci, 2019, 20(1): 19-33. |
14 | DONDELINGER Y, DARDING M, BERTRAND M J, et al. Poly-ubiquitination in TNFR1-mediated necroptosis[J]. Cell Mol Life Sci, 2016, 73(11/12): 2165-2176. |
15 | XU D C, JIN T J, ZHU H, et al. TBK1 suppresses RIPK1-driven apoptosis and inflammation during development and in aging[J]. Cell, 2018, 174(6): 1477-1491.e19. |
16 | WERTZ I, DIXIT V. A20: a bipartite ubiquitin editing enzyme with immunoregulatory potential[J]. Adv Exp Med Biol, 2014, 809: 1-12. |
17 | GONG Y T, FAN Z Y, LUO G P, et al. The role of necroptosis in cancer biology and therapy[J]. Mol Cancer, 2019, 18(1): 100. |
18 | LI X M, LI F, ZHANG X X, et al. Caspase-8 auto-cleavage regulates programmed cell death and collaborates with RIPK3/MLKL to prevent lymphopenia[J]. Cell Death Differ, 2022, 29(8): 1500-1512. |
19 | SALEH D, NAJJAR M, ZELIC M, et al. Kinase activities of RIPK1 and RIPK3 can direct IFN-β synthesis induced by lipopolysaccharide[J]. J Immunol, 2017, 198(11): 4435-4447. |
20 | LINKERMANN A, GREEN D R. Necroptosis[J]. N Engl J Med, 2014, 370(5): 455-465. |
21 | LIU T J, ZONG H F, CHEN X Y, et al. Toll-like receptor 4-mediated necroptosis in the development of necrotizing enterocolitis[J]. Pediatr Res, 2022, 91(1): 73-82. |
22 | BRISSE M, LY H. Comparative structure and function analysis of the RIG-I-like receptors: RIG-I and MDA5[J]. Front Immunol, 2019, 10: 1586. |
23 | ZHANG T, YIN C R, BOYD D F, et al. Influenza virus Z-RNAs induce ZBP1-mediated necroptosis[J]. Cell, 2020, 180(6): 1115-1129.e13. |
24 | LIN J, KUMARI S, KIM C, et al. RIPK1 counteracts ZBP1-mediated necroptosis to inhibit inflammation[J]. Nature, 2016, 540(7631): 124-128. |
25 | DEGTEREV A, OFENGEIM D, YUAN J Y. Targeting RIPK1 for the treatment of human diseases[J]. Proc Natl Acad Sci U S A, 2019, 116(20): 9714-9722. |
26 | DILLON C P, WEINLICH R, RODRIGUEZ D A, et al. RIPK1 blocks early postnatal lethality mediated by caspase-8 and RIPK3[J]. Cell, 2014, 157(5): 1189-1202. |
27 | IMANISHI T, UNNO M, YONEDA N, et al. RIPK1 blocks T cell senescence mediated by RIPK3 and caspase-8[J]. Sci Adv, 2023, 9(4): eadd6097. |
28 | YATIM N, JUSFORGUES-SAKLANI H, OROZCO S, et al. RIPK1 and NF-κB signaling in dying cells determines cross-priming of CD8⁺ T cells[J]. Science, 2015, 350(6258): 328-334. |
29 | MANDAL R, BARRÓN J C, KOSTOVA I, et al. Caspase-8: the double-edged sword[J]. Biochim Biophys Acta Rev Cancer, 2020, 1873(2): 188357. |
30 | WU B Y, LI J Y, WANG H, et al. RIPK1 is aberrantly expressed in multiple B-cell cancers and implicated in the underlying pathogenesis[J]. Discov Oncol, 2023, 14(1): 131. |
31 | CAO L Y, MU W. Necrostatin-1 and necroptosis inhibition: pathophysiology and therapeutic implications[J]. Pharmacol Res, 2021, 163: 105297. |
32 | KATSUYA K, OIKAWA D, IIO K, et al. Small-molecule inhibitors of linear ubiquitin chain assembly complex (LUBAC), HOIPINs, suppress NF- κB signaling[J]. Biochem Biophys Res Commun, 2019, 509(3): 700-706. |
33 | WANG Y K, MA N, XU S, et al. PPDPF suppresses the development of hepatocellular carcinoma through TRIM21-mediated ubiquitination of RIPK1[J]. Cell Rep, 2023, 42(4): 112340. |
34 | JUNG S Y, PARK J I, JEONG J H, et al. Receptor interacting protein 1 knockdown induces cell death in liver cancer by suppressing STAT3/ATR activation in a p53-dependent manner[J]. Am J Cancer Res, 2022, 12(6): 2594-2611. |
35 | YU Y Q, THONN V, PATANKAR J V, et al. SMYD2 targets RIPK1 and restricts TNF-induced apoptosis and necroptosis to support colon tumor growth[J]. Cell Death Dis, 2022, 13(1): 52. |
36 | LIN P H, LIN C L, HE R F, et al. TRAF6 regulates the abundance of RIPK1 and inhibits the RIPK1/RIPK3/MLKL necroptosis signaling pathway and affects the progression of colorectal cancer[J]. Cell Death Dis, 2023, 14(1): 6. |
37 | BAI W Q, CUI F J, WANG Z H, et al. Receptor-interacting protein kinase 1 (RIPK1) regulates cervical cancer cells via NF-κB-TNF-α pathway: an in vitro study[J]. Transl Oncol, 2023, 36: 101748. |
38 | KHAMSEH M E, SHEIKHI A, SHAHSAVARI Z, et al. Evaluation of the expression of necroptosis pathway mediators and its association with tumor characteristics in functional and non-functional pituitary adenomas[J]. BMC Endocr Disord, 2022, 22(1): 1. |
39 | PATEL S, WEBSTER J D, VARFOLOMEEV E, et al. RIP1 inhibition blocks inflammatory diseases but not tumor growth or metastases[J]. Cell Death Differ, 2020, 27(1): 161-175. |
40 | HÄNGGI K, VASILIKOS L, VALLS A F, et al. RIPK1/RIPK3 promotes vascular permeability to allow tumor cell extravasation independent of its necroptotic function[J]. Cell Death Dis, 2017, 8(2): e2588. |
41 | LI Y S, XIONG Y, ZHANG G, et al. Identification of 5-(2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as a new class of receptor-interacting protein kinase 1 (RIPK1) inhibitors, which showed potent activity in a tumor metastasis model[J]. J Med Chem, 2018, 61(24): 11398-11414. |
42 | ZHU G W, DU Q, CHEN X, et al. Receptor-interacting serine/threonine-protein kinase 1 promotes the progress and lymph metastasis of gallbladder cancer[J]. Oncol Rep, 2019, 42(6): 2435-2449. |
43 | MCCORMICK K D, GHOSH A, TRIVEDI S, et al. Innate immune signaling through differential RIPK1 expression promote tumor progression in head and neck squamous cell carcinoma[J]. Carcinogenesis, 2016, 37(5): 522-529. |
44 | CUCHET-LOURENÇO D, ELETTO D, WU C X, et al. Biallelic RIPK1 mutations in humans cause severe immunodeficiency, arthritis, and intestinal inflammation[J]. Science, 2018, 361(6404): 810-813. |
45 | LI Y, FÜHRER M, BAHRAMI E, et al. Human RIPK1 deficiency causes combined immunodeficiency and inflammatory bowel diseases[J]. Proc Natl Acad Sci U S A, 2019, 116(3): 970-975. |
46 | LALAOUI N, BOYDEN S E, ODA H, et al. Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory disease[J]. Nature, 2020, 577(7788): 103-108. |
47 | TAO P F, SUN J Q, WU Z M, et al. A dominant autoinflammatory disease caused by non-cleavable variants of RIPK1[J]. Nature, 2020, 577(7788): 109-114. |
48 | AAES T L, KACZMAREK A, DELVAEYE T, et al. Vaccination with necroptotic cancer cells induces efficient anti-tumor immunity[J]. Cell Rep, 2016, 15(2): 274-287. |
49 | CUCOLO L, CHEN Q Z, QIU J Y, et al. The interferon-stimulated gene RIPK1 regulates cancer cell intrinsic and extrinsic resistance to immune checkpoint blockade[J]. Immunity, 2022, 55(4): 671-685.e10. |
[1] | XUE Yu, ZHANG Hailong, LEI Ming. Expression of cancer-testis antigen SPANXB and its mechanism in affecting hepatocellular carcinoma progress [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(7): 801-813. |
[2] | YANG Shuwen, CHEN Juan, YANG Qin, LEI Ming, HUANG Chenhui. Study on the developmental function of CT14 using the model organism Caenorhabditis elegans [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(7): 871-882. |
[3] | ZHU Mingyang, XU Yuanyuan, REN Jianghao, HUANG Jiazheng, LI Ruonan, TAN Qiang. Review of sublobar resection for lung adenocarcinoma with ground-glass presence [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(7): 922-927. |
[4] | FENG Xujiao, LIU Jianyue, QI Yangyang, SUN Jing, SHEN Lei. Phenotype and function of NK cell in colorectal cancer [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(6): 713-722. |
[5] | YU Yang, MENG Dan, QIU Yiwen, YUAN Jian, ZHU Yingjie. Analysis of impact of type 1 diabetes on colorectal cancer by using two-sample Mendelian randomization [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(6): 755-761. |
[6] | CAI Renjie, XU Ming. KHSRP regulates the responsiveness of prostate cancer cells to androgens through ANK3 [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(4): 417-426. |
[7] | WANG Mengting, CHEN Yinan, XUANYUAN Xinyang, YUAN Haihua. Construction and experimental validation of mouse PDX model by malignant pleural effusion-derived tumor cells from lung cancer [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(4): 435-443. |
[8] | FU Yiling, WU Qian, LUO Xiaoqing, WU Aihong, XIA Xuelan, ZHENG Min. Factors influencing advance care planning engagement behavior in patients with advanced cancer: a systematic review [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(4): 482-493. |
[9] | XU Wenhui, YANG Chang, LI Ruiqing, BIAN Jing, LI Xiayi, ZHENG Leizhen. Exploratory study of interferon regulatory factor 3 promoting proliferation and invasion related to colorectal cancer cells [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(3): 301-311. |
[10] | BAI Wenhui, SHEN Shukun, WU Yingli. Research progress in the anti-cancer activity and related mechanisms of arenobufagin [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(3): 385-392. |
[11] | DING Yanling, LI Jie, YUAN Jun, LI Yan. Research progress in targeted therapies of chronic lymphocytic leukemia [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(2): 264-270. |
[12] | JIANG Shuang, YU Jiwei. Progress of research on m6A demethylases in gastric cancer [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(2): 271-277. |
[13] | ZHU Kaiyuan, SU Yuchen, LIU Zhichao, ZHANG Hong, LI Chunguang, ZHANG Jie, LI Zhigang. Adjuvant strategies for patients with T1b invasion after endoscopic submucosal dissection for esophageal squamous cell carcinoma [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(1): 116-123. |
[14] | YANG Jingxiao, JIA Ziyao, WU Wenguang, WU Xiangsong, ZHANG Fei, LI Huaifeng, ZHU Yidi, LI Maolan. Effect of BRCA1 R1325K mutation on proliferation and apoptosis of gallbladder cancer cells [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(9): 1071-1079. |
[15] | YANG Yue, HE Kaiju, ZONG Jiahao, YANG Ziyi, WU Xiangsong, GONG Wei. Diagnostic value of cell-free DNA to biliary tract cancers: a meta-analysis [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(9): 1175-1185. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||